No Data
Baihua Pharmaceutical: Xinjiang Baihuacun Pharmaceutical Group Co., Ltd. 2024 Annual Results Advance Announcement
Xinjiang Baihuacun Pharmaceutical Group Co., Ltd. 2024 Annual Results Advance Notice
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): The net profit for 2024 is expected to increase by 177.56% to 254.66%.
On January 20, Gelonghui reported that Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced its revenue forecast for 2024. According to preliminary calculations by the company's finance department, it is expected to achieve a Net income attributable to the shareholders of the listed company between 36 million yuan and 46 million yuan, an increase of 177.56% to 254.66% year-on-year. The company expects the Net income attributable to the shareholders of the listed company, excluding non-recurring gains and losses, to be between 28 million yuan and 38 million yuan, an increase of 160.95% to 254.15% year-on-year. During the reporting period, the company intensified market promotion and enhanced its technical capabilities.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Appointed Huang Hui as the company's rotating general manager.
On December 19, Gelonghui reported that Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced the holding of the third meeting of its ninth Board of Directors on December 19, 2024. The meeting reviewed and approved the proposal regarding the appointment of the company's rotating general manager for 2025. In accordance with the relevant provisions of the company's articles of association and the management system for rotating general managers, Mr. Huang Hui was nominated by the company's chairman and approved by the Board of Directors' nomination committee. The Board of Directors has agreed to appoint Mr. Huang Hui as the company's rotating general manager for 2025, for a term of one year.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Shareholders have signed a concerted action agreement.
Gelonghui December 2nd | Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that it has received the "Consolidated Action Agreement" signed by Mr. Mi Zaiqi, Mr. Mi Enhua, Ms. Yang Xiaoling, and Mr. Li Jiancheng, the actual controllers of the company. The three individuals still collectively constitute the actual controllers of the company, with a total holding of 79,525,087 shares, accounting for 20.71% of the company's total share capital. The three joint controllers and Li Jiancheng have re-signed the Consolidated Action Agreement, and Li Jiancheng, as a joint controller, still directly holds 15,000,000 shares of the company, accounting for 3.91% of the company's total share capital. The three joint controllers and one of them.
Report for the third quarter of 2024 of Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.
